Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.48 |
| ▸ | USP14 | P54578 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144600 | 0.91 | ALDH1A1 (0.51) | RENUSP14ALDH1A1MEN1KMT2A | |
| SCHEMBL3403996 | 0.88 | REN (0.54) | RENUSP14ALDH1A1MEN1KMT2A | |
| SCHEMBL1144092 | 0.83 | ALDH1A1 (0.61) | RENUSP14ALDH1A1MEN1KMT2A | |
| SCHEMBL1144771 | 0.80 | REN (0.69) | REN | |
| SCHEMBL1149907 | 0.80 | REN (0.47) | RENUSP14MEN1KMT2AGPR119 | |
| SCHEMBL1144687 | 0.80 | REN (0.53) | RENALDH1A1MEN1KMT2ASTS | |
| SCHEMBL1144756 | 0.79 | KDM4E (0.47) | RENUSP14MEN1KMT2AKDM4E | |
| SCHEMBL1144661 | 0.78 | ALDH1A1 (0.44) | RENALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL1144191 | 0.77 | CHRM2 (0.52) | RENMEN1KMT2AGPR119TP53 | |
| SCHEMBL1144332 | 0.76 | REN (0.65) | RENALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247575-B1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-23 | — | — | EP | disclosed |
| US-8211885-B2 | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | REN 1/4885USP14 1913/4885ALDH1A1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.